• Successful launch of the new Empliq range of human tissue products in the US
• Empliq range complements ReNerve's existing nerve repair product portfolio
• First sale of the Empliq Dermal deep-layer matrix product, with amniotic and placental allograft products to follow in Q3 CY25

ReNerve Limited (ASX:RNV), an ASX listed medical device company developing innovative products for peripheral nerve injury ('PNI') repair, has successfully launched its Empliq range of human tissue products after recently completing first sales. The new product range is now available in the US, with ReNerve to implement market launch activities at the upcoming American Society for Surgery of the Hand (ASSH) conference in Vancouver in the first half of October. Developed in conjunction with its partner Berkeley Biologics, the Empliq product range is complementary to the existing ReNerve product portfolio, focusing on a range of indications already targeted by ReNerve. The first sale, of the Empliq Dermal deep-layer matrix product, precedes the amniotic and placental allograft products reaching the market in Q3 CY25. ReNerve CEO Dr Julian Chick stated that the launch of the Empliq range is a key step in the company's strategy to provide a broad suite of products to surgeons, while complementing its existing nerve repair product range. The company has developed and completed all the branding and marketing materials for Empliq, and the products are now available to the sales teams across the US. ReNerve looks forward to providing continued updates as the Empliq range gains traction in the market.

The dermal and amniotic tissue market is estimated to reach more than $1.5 billion in 2026 and more than $3 billion by 2032.